Portal de Periódicos da CAPES

Reiter?s syndrome following intravesical bacille bili� de Calmette?Gu�rin treatment for superficial bladder carcinoma: report of six cases

2004; Oxford University Press; Volume: 14; Issue: 1 Linguagem: Inglês

10.1007/s10165-003-0272-3

1439-7609

Hideyuki Murata, Yoshihiro Adachi, T. Ebitsuka, Yusuke Chino, Reiko Takahashi, Taichi Hayashi, Daisuke Goto, Isao Matsumoto, Akito Tsutsumi, Hideyuki Akaza, Takayuki Sumida,

Urinary and Genital Oncology Studies

We report the cases of six patients who developed acute Reiter’s syndrome following intravesical bacille bilié de Calmette–Guérin (BCG) immunotherapy for superficial bladder cancer. After the third to eighth BCG intravesical injection, the patients developed conjunctivitis, aseptic urethritis, and polyarthritis consistent with a diagnosis of Reiter’s syndrome. HLA-B27 antigen was negative in five of the patients examined. Two of the patients responded to nonsteroidal anti-inflammatory drugs for polyarthritis, and the other four responded to steroids (prednisolone 5–10 mg/day). The frequent use of intracavitary BCG may increase the incidence of BCG-induced Reiter’s syndrome. Further analysis of the relationship between HLA-B and -DR alleles and arthritis should shed light on the mechanism of BCG-induced Reiter’s syndrome.